 GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 16, 2020 GLOBE NEWSWIRE -- Applied Genetic Technologies Corporation Nasdaq: AGTC, a biotechnology company conducting human clinical trials of adeno-associated virus AAV-based gene therapies for the treatment of rare diseases, today announced financial results for the quarter ended September 30, 2020. The Company is also providing an update on its ongoing clinical trials in patients with X-linked retinitis pigmentosa XLRP and achromatopsia ACHM. 